Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127000 | 0.85 | TSHR (0.65) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| SCHEMBL29637724 | 0.85 | TSHR (0.65) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| SCHEMBL727333 | 0.85 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3842507 | 0.83 | MAPK1 (0.46) | ALDH1A1TSHRSMN1; SMN2NPC1RAB9A | |
| Fluoride SCHEMBL27757467 | 0.83 | TSHR (0.62) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| Phosphine SCHEMBL22634020 | 0.83 | TSHR (0.62) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| SCHEMBL28342363 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| SCHEMBL4701431 | 0.82 | L3MBTL1 (0.50) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL31448640 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 | |
| SCHEMBL31448448 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TSHRSMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-3227269-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| CN-106458914-B | Heterocyclic compounds as AXL inhibitors | 常州捷凯医药科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| WO-2015143692-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2015-10-01 | — | — | WO | disclosed |
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2010488-A2 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | ALDH1A1 1625/4885TSHR 2126/4885SMN1; SMN2 4034/4885 |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, MERTK | ALDH1A1 3773/4885TSHR 208/4885SMN1; SMN2 1298/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | ALDH1A1 1084/4885TSHR 3514/4885SMN1; SMN2 3061/4885 |
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | ALDH1A1 1056/4885TSHR 2555/4885SMN1; SMN2 3337/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | ALDH1A1 1060/4885TSHR 3978/4885SMN1; SMN2 1848/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | ALDH1A1 2221/4885TSHR 3864/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.